Pulmonary Embolism Registry from Emergency Care to Long-Term Follow-Up

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

PERSEUS is an academic, multicenter registry that collects real-world data on adults with acute pulmonary embolism from pre-hospital care through long-term follow-up. It includes both retrospective data from patients diagnosed since January 1, 2023 and prospective enrollment for up to 5 years, with no changes to how patients are treated. The study aims to describe everyday management, short-term stability, and long-term outcomes, including death from any cause and PE-related events. Data are gathered during routine care across participating Italian centers, spanning emergency departments, hospital stays, and follow-up visits. The registry emphasizes dynamic risk stratification during the initial 48 hours and long-term surveillance to improve understanding of PE trajectories.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18 years or older at the time of presentation.
* Objectively confirmed diagnosis of acute pulmonary embolism (PE), with or without concomitant deep vein thrombosis (DVT) of the lower or upper extremities, confirmed by at least one of the following methods:
* Computed tomography pulmonary angiography (CTPA) demonstrating intraluminal filling defects in the pulmonary arterial tree;
* Ventilation/perfusion (V/Q) lung scintigraphy demonstrating high-probability mismatch;
* Conventional catheter-directed pulmonary angiography;
* In hemodynamically unstable patients (obstructive shock or cardiac arrest) in whom definitive imaging is not feasible: bedside point-of-care ultrasound showing clear signs of right ventricular overload together with proximal deep vein thrombosis, or mobile right heart thrombi.
* For the retrospective cohort: availability of medical records documenting clinical presentation and index diagnostic work-up at baseline (T0). The absence of serial reassessment timepoints (T1-T4) does not constitute an exclusion criterion.
* Written informed consent obtained from the patient or legal surrogate, or waiver/exception under Article 110-bis of the Italian Privacy Code (and applicable institutional ethical clearance) for deceased or untraceable patients.

Exclusion Criteria:

* Current active enrollment in an interventional experimental drug trial (blinded randomized clinical trial) where active drug allocation or protocol-mandated therapeutic regimen is unknown.

Where it's running

• Ospedale Santa Maria Annunziata - Azienda USL Toscana Centro
  Bagno a Ripoli, Tuscany, Italy Recruiting
• Nuovo Ospedale del Mugello - Azienda USL Toscana Centro
  Borgo San Lorenzo, Tuscany, Italy Recruiting
• Ospedale San Giuseppe - Azienda USL Toscana Centro
  Empoli, Tuscany, Italy Recruiting
• Ospedale Santa Maria Nuova - Azienda USL Toscana Centro
  Florence, Tuscany, Italy Recruiting
• Azienda Ospedaliero-Universitaria Careggi
  Florence, Tuscany, Italy Recruiting
• Ospedale San Giovanni di Dio (Torregalli) - Azienda USL Toscana Centro
  Florence, Tuscany, Italy Recruiting

Study contacts

• Principal investigator: Simone Vanni, MD, PhD — Azienda Ospedaliero-Universitaria Careggi / University of Florence
• Study coordinator: Simone Vanni, MD, PhD
• Email: simone.vanni@unifi.it
• Phone: +393666904459

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating and improving diagnostics and management of venous thromboembolism

  This study is trying to find better ways to diagnose and manage blood clots in the veins for older patients who might have deep vein thrombosis or pulmonary embolism.

  Recruiting Johannes Gutenberg University Mainz · Mainz, Rhineland-Palatinate · NCT02156401

• Aspirin vs. rivaroxaban for blood clot prevention in newly diagnosed multiple myeloma

  In newly diagnosed multiple myeloma patients on IMiD-based therapy, this study tests whether aspirin or rivaroxaban is better at preventing blood clots.

  Recruiting Phase 4 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07907211

• TRiP-cast score test in adults with acute lower-limb injuries requiring immobilization

  This study tests whether the TRiP(cast) score can predict risk of blood clots in adults with acute lower-limb injuries treated as outpatients.

  Recruiting University of Monastir · Monastir · NCT07863115

• YKYY033 Injection safety and tolerability in adults

  This study tests whether a single dose of YKYY033 injection is safe and tolerable in healthy adults aged 18–55.

  Recruiting Phase 1 Youcare Pharmaceutical Group Co., Ltd. · Beijing, Beijing Municipality · NCT07786779

• Nailfold Capillaroscopy in Pulmonary Hypertension

  This study tests whether nailfold capillary scans correlate with invasive lung blood pressure measurements and whether these patterns change with PH treatment.

  Recruiting University of Glasgow · Clydebank, West Dunbartonshire · NCT07768644

• Blood-clot prevention with REGN7508 and REGN9933 in people with PICC lines

  This study tests whether REGN7508 and REGN9933 can help prevent blood clots in people who have a PICC line.

  Recruiting Phase 3 Regeneron Pharmaceuticals · Tbilisi · NCT07697599

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.